SBTX — Skinbiotherapeutics Share Price
Last trade - 00:00- £18.54m
- £15.79m
- £0.13m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.08 | ||
| Price to Tang. Book | 6.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 114.66 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -81.77% | ||
| Return on Equity | -118.64% | ||
| Operating Margin | -1877.19% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | 0.07 | 0.13 | 1.1 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SkinBioTherapeutics plc is a United Kingdom-based life science company, which is focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Company’s segments include UK, US, and EU. The Company's platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company is targeting five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. The Company's product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis. The Company is also focused on the application of SkinBiotix technology in the treatment of various classes of skin wounds.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 10th, 2015
- Public Since
- April 5th, 2017
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 200,379,907
- Address
- The Core, Newcastle Helix, NEWCASTLE UPON TYNE, NE4 5TF
- Web
- https://www.skinbiotherapeutics.com/
- Phone
- +44 1914957325
- Auditors
- Gravita Audit Limited
Latest News for SBTX
Upcoming Events for SBTX
Similar to SBTX
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 07:20 UTC, shares in Skinbiotherapeutics are trading at 9.25p. This share price information is delayed by 15 minutes.
Shares in Skinbiotherapeutics last closed at 9.25p and the price had moved by -37.29% over the past 365 days. In terms of relative price strength the Skinbiotherapeutics share price has underperformed the FTSE All Share Index by -39.27% over the past year.
The overall consensus recommendation for Skinbiotherapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Skinbiotherapeutics does not currently pay a dividend.
Skinbiotherapeutics does not currently pay a dividend.
Skinbiotherapeutics does not currently pay a dividend.
To buy shares in Skinbiotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 9.25p, shares in Skinbiotherapeutics had a market capitalisation of £18.54m.
Here are the trading details for Skinbiotherapeutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: SBTX
Based on an overall assessment of its quality, value and momentum Skinbiotherapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Skinbiotherapeutics is 48.00p. That is 418.92% above the last closing price of 9.25p.
Analysts covering Skinbiotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -£0.02 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Skinbiotherapeutics. Over the past six months, its share price has underperformed the FTSE All Share Index by -70.47%.
As of the last closing price of 9.25p, shares in Skinbiotherapeutics were trading -43.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Skinbiotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 9.25p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Skinbiotherapeutics' management team is headed by:
- Martin Hunt - NEC
- Stuart Ashman - CEO
- Douglas Quinn - CFO
- Catherine Prescott - NID